SCHEMBL4024718

SCHEMBL4024718

Cc1c(F)cccc1C1C(C(=O)c2cccc(O)c2)CN(CCNS(C)(=O)=O)CC1C(=O)c1cccc(O)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
KDM1A O60341 2/20 0.33
KDM2B Q8NHM5 2/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GSK3B P49841 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
POLB P06746 2/20 0.31
MGLL Q99685 1/20 0.31
GAA P10253 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
ALOX15 P16050 1/20 0.31
NFKB1 P19838 1/20 0.31
PMP22 Q01453 1/20 0.31
HTR4 Q13639 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021154 1.00 KDM4E (0.34) KDM4EMAPTPKMOPRM1OPRD1
SCHEMBL13721491 1.00 KDM4E (0.34) KDM4EMAPTPKMOPRM1OPRD1
SCHEMBL4022700 0.92 DPP4 (0.34) KDM4EMAPTPKMKDM2BMGLL
SCHEMBL4022460 0.90 OPRM1 (0.33) OPRM1OPRD1KDM2BMEN1KMT2A
SCHEMBL4029451 0.90 CARM1 (0.37) OPRM1OPRD1KDM2BMEN1KMT2A
SCHEMBL4025226 0.88 OPRM1 (0.35) KDM4EOPRM1KDM2BMEN1KMT2A
SCHEMBL4025235 0.88 OPRM1 (0.35) KDM4EOPRM1KDM2BMEN1KMT2A
SCHEMBL4024482 0.86 KDM2B (0.35) KDM4EOPRM1OPRD1KDM2BMEN1
SCHEMBL4024480 0.86 KDM2B (0.35) KDM4EOPRM1OPRD1KDM2BMEN1
SCHEMBL4020633 0.86 MEN1 (0.35) OPRM1OPRD1KDM2BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KDM4E 4110/4885MAPT 3009/4885PKM 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.